Key points are not available for this paper at this time.
In the Clarity AD Asian region cohort, the overall efficacy, biomarker changes and safety profile of lecanemab were consistent with the overall population, with a favorable risk-benefit profile and manageable risks. ARIA events and infusion-related reactions occurred less commonly with lecanemab in the Asian region subgroup than the overall population.
Building similarity graph...
Analyzing shared references across papers
Loading...
Christopher Chen
Rutgers, The State University of New Jersey
Sadao Katayama
Kurashiki Medical Center
Jae Hong Lee
Ulsan College
The Journal of Prevention of Alzheimer s Disease
National University of Singapore
Seoul National University
University of Ulsan
Building similarity graph...
Analyzing shared references across papers
Loading...
Chen et al. (Mon,) studied this question.
synapsesocial.com/papers/69dc0afd2f8392c28b2a6577 — DOI: https://doi.org/10.1016/j.tjpad.2025.100160